Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > BUSINESS
BUSINESS
- Japan’s Diabetes Market to Exceed 600 Billion Yen in 2023: Fuji Keizai
August 14, 2015
- Kyowa Kirin Looks to Derive 40% of Sales Overseas by 2020, Split from Holdings Firm Won’t Happen: Pres.
August 13, 2015
- Hospira Japan’s Generic Oxaliplatin Approved for Gastric Cancer
August 13, 2015
- Ethical Drug Sales Up 9.8% in June: Crecon Report
August 13, 2015
- INCJ Invests 600 Million Yen in Drug Discovery Venture Founded by Tokyo Medical and Dental Univ.
August 12, 2015
- ASCO Immunotherapy Roundup - 6: CAR T-Cell Therapy Another Hot Field in Immuno-Oncology
August 12, 2015
- Quintiles to Set Up Unit for Medical Devices and Regenerative Medicines
August 12, 2015
- Biogen Japan Expects Continued Growth Past 2020 through Major New Drugs
August 11, 2015
- Long-Acting Injectable Version of Abilify Entering Accelerated Growth Phase: Pres. Higuchi of Otsuka Holdings
August 11, 2015
- Sublingual Immunotherapy Tablet for Pollinosis Shows Efficacy in PII/PIII Study in Japan: Torii
August 11, 2015
- Denki Kagaku Kogyo to Acquire Germany’s Biopharma Icon Genetics
August 11, 2015
- Drug Wholesalers Suffer 1st Sales Drop since 1997
August 10, 2015
- Sumitomo Dainippon Will Be Able to Cover the Loss of Long-Listed Drug Sales: President
August 10, 2015
- Pharmaceutical Sales Down 2.4% in 1st Half Due to Loss of Patent Protection for Abilify in US: Otsuka Holdings
August 10, 2015
- Sosei’s UK Subsidiary, AZ Partner for Development of Cancer Immunotherapies
August 10, 2015
- ASCO Immunotherapy Roundup - 5: Merck & Co. Discovers New Biomarkers for Keytruda
August 7, 2015
- Sanofi Files NDA for Hypercholesterolemia Treatment Alirocumab in Japan
August 7, 2015
- Pfizer Japan Pays 14.8 Billion Yen to Doctors, Medical Institutions in FY2014 under Transparency Guidelines
August 7, 2015
- Japan Pharma Market Up 7.9% in April-June 2015: IMS
August 6, 2015
- 14-Day Limit on Prescriptions Considered Unnecessary from a Safety Standpoint in the US and Europe: Pfizer Pres. Umeda
August 6, 2015
ページ
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…